Vithai Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 20 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 M
- Revenue Growth 455.07%
- Profit Growth 135.58%
- Ebitda 659.42%
- Net Worth 16.41%
- Total Assets 13.91%
About Vithai Pharmaceuticals
Vithai Pharmaceuticals Private Limited (VPPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 April 2004 and has a history of 20 years and nine months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.00 M.
Shekhar Chandorkar and Saroj Chandorkar serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230MH2004PTC146005
-
Company No.
146005
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
30 Apr 2004
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Vithai Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shekhar Chandorkar
|
Director | 30-Apr-2004 | Current |
|
Saroj Chandorkar
|
Director | 30-Apr-2004 | Current |
Financial Performance of Vithai Pharmaceuticals.
Vithai Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 455.07% increase. The company also saw a substantial improvement in profitability, with a 135.58% increase in profit. The company's net worth Soared by an impressive increase of 16.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vithai Pharmaceuticals?
In 2020, Vithai Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Apr 2012 | Others | ₹2.00 M | Open |
How Many Employees Work at Vithai Pharmaceuticals?
Unlock and access historical data on people associated with Vithai Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vithai Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vithai Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
